The effectiveness of chemotherapy was enhanced by targeting survivin, a protein that inhibits apoptosis or cell death, according to preclinical research in cells and mouse models of retinoblastoma.
A small, phase I clinical trial indicates the experimental drug guadecitabine is safe in combination with the chemotherapy drug irinotecan, and it may overcome resistance to irinotecan in patients with metastatic colorectal cancer.
Continuation of ceritinib therapy beyond disease progression was associated with prolonged survival, according to results from a retrospective study of the use of ceritinib to treat advanced ALK-positive NSCLC.
Some of our patients receive olanzapine (Zyprexa) as an antiemetic. Is this a typical use of this drug?
Microneedles embedded in a patch deliver cancer immunotherapy treatment directly to the site of melanoma, according to preliminary findings in animal studies.
The growth of medulloblastoma was inhibited by a new drug in research conducted in cell cultures and mice. This study targeted a particularly aggressive form of the disease driven by the oncogene MYC.
Sulforaphane, found in broccoli and other cruciferous vegetables such as cauliflower and kale, may increase the susceptibility of a subset of cancer to prodrug treatments while avoiding harm to normal tissues.
New research has shed light on how some tumors continue their growth despite treatment with kinase inhibitors, and on how a combination of drugs can yield much better results.
A new drug might help successfully treat mesothelioma, one of the deadliest cancers, according to results from cell culture and mouse xenograft models of the disease.
A subtype-specific weakness of T-cell acute lymphoblastic leukemia (T-ALL) could enable improved treatment, according to results from a a recent study using a mouse model.
A new therapy might help treat a rare, high-risk cancer that begins development in the fetus or embryo, neuroblastoma, according to recent results from cell culture experiments.
Adding Palbociclib to Fulvestrant Improves Progression-free Survival in Select Women With Metastatic Breast CancerMarch 22, 2016
Progression-free survival was significantly and consistently improved when palbociclib was added to fulvestrant, compared with placebo and fulvestrant, for women with stage IV breast cancer that is hormone-receptor-positive and HER2-negative.
Combining birinapant with a p38 inhibitor is a promising therapeutic regimen for patients with acute myeloid leukemia (AML).
An implantable device allows large doses of highly toxic drugs to be delivered directly to pancreatic tumors while reducing exposure to the toxic side effects in the rest of the body.
How is loratadine used to treat bone pain in patients receiving white blood cell growth factors?
Medications normally used to treat infections and heart conditions are promising cancer treatments. These drugs were previously not known to have roles in modifying cellular epigenetics.
An exploration of the interaction between the protein produced by the common cancer-causing KRAS gene and the AGO2 protein may lead to the possibility of interrupting the KRAS-AGO2 interaction as a possible therapy.
The growth of castration-resistant prostate cancer cells was reduced by a first-in-class sphingosine kinase 2 inhibitor, but the cells were not killed.
Combining a drug indicated for melanoma with a common cholesterol-lowering drug may control the growth of NSCLC, according to research in fruit flies and human lung cancer cell lines.
Nanoparticles that release a drug only when exposed to near-infrared (NIR) light are a promising drug-delivery agent developed by Canadian researchers.
Use of a nanoparticle to deliver drugs may reduce tumors and suppress metastatic escape. These efforts offer a way to control drug release over space and time while reducing systemic drug exposure and the associated side effects.
Exosome serves as a natural nanoparticle delivery system and achieves the same cancer-killing effect on drug-resistant lung cancer as current formulations of drug therapy with 50x less drug.
A new analysis of a phase III trial of patients with neuroendocrine tumors that began in the gastrointestinal (GI) tract or at an unknown primary location found that progression-free survival was improved with everolimus by 6 to 8 months compared with placebo.
A drug currently approved for GI conditions may prevent the development of colorectal cancer, according to researchers who revealed a biological connection between obesity and increased risk for colorectal cancer.
Patients with breast cancer whose health insurance plans included prescription drug benefits were 10% more likely to start important hormonal therapy than patients who did not have prescription drug coverage.
Women who have ovarian cancer often develop ascites, a buildup of fluids in the abdomen. Researchers have found that ascites can be reduced with minimal side effects through inhibition of the colony-stimulating-factor-1 receptor (CSF1R).
Researchers announced a breakthrough advance in a world-first international clinical trial of a new drug to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma that is refractory or resistant to current chemotherapies.
Recent laboratory findings provide novel insight into potential new therapeutic approaches for triple-negative breast cancer, a particularly difficult-to-treat and aggressive form of the disease.
Atezolizumab may substantially change treatment strategies for patients with refractory lung cancer, according the first efficacy results from the POPLAR and BIRCH studies, which studied the PD-L1 antibody across treatment lines.
Current results from a clinical trial comparing a combination of two targeted therapies with a single-agent treatment for advanced melanoma has shown patients are living significantly longer with the combination therapy.
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Navigator-specific Interventions and Multidisciplinary Care Team Collaboration Improves Care and Outcomes for Patients with GI Cancers
- Antibody Therapy Reduces Numbers of Cancer Stem Cells in Patients With Multiple Myeloma
- Oncology Nurses Should Be Aware of Complexities of Neuroendocrine Tumors
- Diet Can Affect Aggressiveness of Prostate Cancer
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Acupuncture Improves Management of Hot Flashes, Quality of Life in Breast Cancer
- Higher Vitamin D Levels Lower Risk of Cancer in Women
- Getting Started: Implementation of an Oncology Navigation Program That Meets Community Needs
- Beyond Treatment: Anticipating the Late Effects of Cancer Treatment in Survivors
- Oral Chemotherapy Care Model Improves Safety, Quality Through Increased Collaboration
- Follow-up Calls, Clinician Assessment May Identify Patients Who Need Adherence Support
- Precision Medicine Resource Center Improves Patient Education
- Inpatient Oral Chemotherapy Administration Process Developed to Comply With Safety Standards
- Formal Nursing Practice Promotes Patient Safety With Oral Chemotherapy
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|